Anti-Factor-Xa and Activated Partial Thromboplastin Time Concordance and Outcomes in Adults Undergoing Extracorporeal Membrane Oxygenation: A Secondary Analysis of the Pilot Low-Dose Heparin in Critically Ill Patients Undergoing Extracorporeal Membrane Oxygenation Randomized Trial
Authors:
Open Access
- 8 November 2023
- journal article
- research article
- Published by Wolters Kluwer Health in Critical Care Explorations
- Vol. 5 (11) , e0999
Abstract
OBJECTIVES: To determine the concordance between activated partial thromboplastin time (aPTT) and anti-factor-Xa (anti-Xa) in adults undergoing extracorporeal membrane oxygenation (ECMO) and to identify the factors associated with discordant paired aPTT/anti-Xa. DESIGN: Pre-planned secondary analysis of the Low-Dose Heparin in Critically Ill Patients Undergoing Extracorporeal Membrane Oxygenation pilot randomized unblinded, parallel-group controlled trial. SETTING: Two ICUs in two university hospitals. PATIENTS: Thirty-two critically ill patients who underwent ECMO and who had at least one paired aPTT and anti-Xa assay performed at the same time. INTERVENTIONS: We analyzed the concordance between aPTT and anti-Xa and identified factors associated with discordant paired aPTT/anti-Xa based on their respective therapeutic ranges. We also compared biological parameters between heparin resistance episode and no heparin resistance. MEASUREMENTS AND MAIN RESULTS: Of the 32 patients who were included in this study, 24 (75%) had at least one discordant paired aPTT/anti-Xa. Of the 581 paired aPTT/anti-Xa that were analyzed, 202 were discordant. The aPTT was relatively lower than anti-Xa in 66 cases (32.7%) or relatively higher than anti-Xa in 136 cases (67.3%). Thirty-three heparin resistance episodes were identified in six patients (19%). CONCLUSIONS: In these critically ill patients undergoing ECMO, one third of paired aPTT/anti-Xa measures was discordant. Coagulopathy and heparin resistance might be the reasons for discordance. Our results support the potential importance of routinely monitoring both tests in this setting.Keywords
Funding Information
- Australian and New Zealand College of Anaesthetists (2015/007)
This publication has 25 references indexed in Scilit:
- Guidance for the practical management of the heparin anticoagulants in the treatment of venous thromboembolismJournal of Thrombosis and Thrombolysis, 2016
- Predictive factors of bleeding events in adults undergoing extracorporeal membrane oxygenationAnnals of Intensive Care, 2016
- Extracorporeal Membrane Oxygenation—Hemostatic ComplicationsTransfusion Medicine Reviews, 2015
- Neurologic Complications of Extracorporeal Membrane OxygenationJournal of Clinical Neurology, 2015
- Unfractionated Heparin Activity Measured by Anti-Factor Xa Levels Is Associated With the Need for Extracorporeal Membrane Oxygenation Circuit/Membrane Oxygenator ChangePediatric Critical Care Medicine, 2014
- Anti-Factor Xa Assay Is a Superior Correlate of Heparin Dose Than Activated Partial Thromboplastin Time or Activated Clotting Time in Pediatric Extracorporeal Membrane Oxygenation*Pediatric Critical Care Medicine, 2014
- Discordant aPTT and Anti-Xa Values and Outcomes in Hospitalized Patients Treated with Intravenous Unfractionated HeparinAnnals of Pharmacotherapy, 2013
- Antifactor Xa Levels versus Activated Partial Thromboplastin Time for Monitoring Unfractionated HeparinPharmacotherapy: The Journal of Human Pharmacology and Drug Therapy, 2012
- The SOFA (Sepsis-related Organ Failure Assessment) score to describe organ dysfunction/failureIntensive Care Medicine, 1996
- A Randomized Trial Comparing Activated Thromboplastin Time With Heparin Assay in Patients With Acute Venous Thromboembolism Requiring Large Daily Doses of HeparinArchives of internal medicine (1960), 1994